A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
- Status
- RECRUITING
- Phase
- NA
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib
- Status
- RECRUITING
- Phase
- PHASE2
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Status
- WITHDRAWN
- Phase
- PHASE3
Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
- Status
- TERMINATED
- Phase
- PHASE1
Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Status
- COMPLETED
- Phase
- N/A
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2